Related Experiment Videos
Reevaluation of the Cottbus Reinfarction Study with 30 mg aspirin per day 4 years after the end of the study
W Hoffmann1, M Nitschke, J Muche
1District Hospital, Cottbus, GDR.
Insights
Low-dose aspirin (30 mg) significantly reduced reinfarction rates compared to high-dose aspirin (1000 mg) in post-heart attack patients. Long-term follow-up showed lower non-fatal reinfarctions with continued low-dose aspirin therapy.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Medicine
Background:
- The Cottbus Reinfarction Study investigated aspirin dosages (30, 60, 1000 mg/day) post-myocardial infarction.
- Long-term outcomes and patient adherence to aspirin regimens were assessed years after the initial study.
Purpose of the Study:
- To evaluate the long-term efficacy of different aspirin dosages on reinfarction rates.
- To assess patient adherence to prescribed aspirin doses after myocardial infarction.
Main Methods:
- Survivors from the original study (4-6 years post-intervention) were re-evaluated.
- Patient adherence to previous aspirin dosages was recorded.
- Reinfarction rates (total and non-fatal) were compared between dosage groups.
Main Results:
- Aspirin adherence varied, with most 30 mg patients continuing low doses, while 1000 mg patients often reduced their intake.
- Total reinfarction rates were higher in the prior 1000 mg group (22.5%) versus the 30 mg group (17.4%).
- Non-fatal reinfarctions were 50% lower in the former 30 mg group compared to the 1000 mg group, particularly in the 50-59 age bracket.
Conclusions:
- Long-term use of low-dose aspirin (30 mg) is associated with significantly lower reinfarction rates compared to high-dose aspirin.
- Patient adherence plays a role in long-term outcomes, with a trend towards lower doses post-myocardial infarction.
- Low-dose aspirin therapy appears to be a more effective strategy for preventing recurrent myocardial infarction.
Abstract:
Four to 6 years after the end of the Cottbus Reinfarction Study with 30, 60 and 1000 mg/day aspirin, the survivors (72% of the patients) were reevaluated under standardized conditions at the district hospital. Nearly all patients (82%) of the former 30 mg group took further on 30 mg aspirin daily whereas of the former 1000 mg group only 20% continued to take doses higher than 500 mg aspirin. Forty-five percent changed to very low doses. Whereas the death rate was nearly the same in all three former dosage groups the total reinfarction rate was higher (22.5%) in the previous 1000 mg group in comparison to the 30 mg group (17.4%, p less than 0.05). The non-fatal reinfarction rate was by 50% lower in the former 30 mg group compared with the previous 1000 mg group. In the age group 50-59 a 8.6% non-fatal reinfarction rate is contrasted to 1.7% reinfarctions in patients of the former 30 mg group (p less than 0.01). The risk factors were not significantly different in the three groups.